~~Table~~UNITED ofSTATES SECURITIES ~~Contents~~AND EXCHANGE COMMISSION Washington, D.C. 20549

~~UNITED~~FORM ~~STATES~~8-K ~~SECURITIES AND EXCHANGE COMMISSION~~

~~Washington,~~CURRENT DCREPORT Pursuant ~~20549~~to Section 13 OR 15(d) of The Securities Exchange Act of 1934

~~FORM~~Date ~~8-K~~of Report (Date of earliest event reported): March 10, 2008

~~Current~~LEINER ~~Report Pursuant~~HEALTH ~~to Section 13 or 15~~PRODUCTS INC. (d)Exact name of ~~the~~registrant ~~Securities~~as specified ~~Exchange~~in ~~Act~~its ofcharter) ~~1934~~

Date of Report (Date of earliest event reported) September 17, 2007


DELAWARE	333-33121	95-3431709
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

LEINER HEALTH PRODUCTS INC.


901 East 233rd Street, Carson, California		90745
(Address of Principal Executive Offices)		(Zip Code)

~~(Exact~~Registrant’s ~~name~~telephone ofnumber, including ~~registrant~~area ascode: ~~specified in its charter~~(310) 835-8400

DELAWARE (State or other jurisdiction of incorporation or organization)		333-33121 (Commission File Number)		95-3431709 (IRS Employer Identification Number)
901 East 233rd Street, Carson, California (Address of principal executive offices)				90745 (Zip Code)

N/A

(Former name or former address if changed since last report.)

~~Registrant’s~~Check ~~telephone~~the ~~number,~~appropriate ~~including~~box ~~area~~below ~~code~~if ~~(310) 835~~the Form 8-~~8400~~K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (~~Former~~17 ~~name~~CFR 230.425) o orSoliciting ~~former~~material ~~address,~~pursuant to ifRule ~~changed~~14a-12 ~~since~~under ~~last~~the ~~report~~Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~o Written communications pursuant to Rule~~Section ~~425~~1 ~~under~~– Registrant’s ~~the~~Business ~~Securities~~and ~~Act (17 CFR 230.425)~~Operations

oItem ~~Soliciting~~1.03 ~~material~~Bankruptcy ~~pursuant~~or ~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~ Receivership

oOn ~~Pre-commencement~~Monday, March 10, ~~communications~~2008, ~~pursuant~~Leiner toHealth ~~Rule 14d-2~~Products Inc (bthe “Company”) filed a voluntary petition under Chapter 11 of the ~~Exchange~~United ~~Act~~States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (17the ~~CFR~~“Bankruptcy ~~240~~Court”) (Case No.~~14d~~ 08-~~2(b~~10446)), along with the Company’s parent, LHP Holding Corp., and the Company’s subsidiaries, Leiner Health Products, LLC and Leiner Health Services Corp. The Company has requested that, for administrative purposes, the Bankruptcy Court consolidate these cases for joint administration. The Company will continue to operate its business as a “debtor in possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code.

oConcurrently, ~~Pre-commencement~~the ~~communications~~Company ~~pursuant~~issued tothe ~~Rule 13e-4(c)~~press ~~under~~release ~~the~~filed ~~Exchange~~herewith ~~Act~~as Exhibit 99.1, ~~(17~~relating ~~CFR~~to ~~240~~the foregoing.~~13e-4(c))~~

~~-1-~~Section 9 – Financial Statements and Exhibits

~~TABLE~~Item OF9.01 ~~CONTENTS~~Financial Statements and Exhibits

Item 8.01 Other Events. SIGNATURE


(c)	Exhibits
		99.1	Press Release dated March 10, 2008.

~~Table~~- of2 ~~Contents~~-

~~As previously disclosed on Form 8-K on September 11, 2007, we became aware of a Department of~~SIGNATURE ~~Justice investigation relating to the production, control, and distribution of certain~~ over-the-counter drug products at our Fort Mill Facility, which we believe concerns certain activities relating to the observations included in a Form 483 report we received from the Food and Drug Administration.

WePursuant ~~will~~to ~~hold~~the requirements aof ~~conference~~the ~~call~~Securities onExchange ~~Tuesday,~~Act ~~September 18,~~of ~~2007~~1934, ~~at 12:00 p.m. Eastern Time regarding these events. The dial-in number for~~ the ~~conference~~Registrant ~~call~~has ~~is (877) 278-2335 for domestic~~duly ~~callers~~caused ~~and~~this ~~(706) 634-0167~~report ~~for international callers. Participants should enter “17325637” as the ID number~~ to ~~participate in the conference call. For those who cannot listen to the live broadcast, a telephone replay of the call will~~ be ~~available~~signed ~~from~~on ~~September 18,~~its ~~2007~~behalf ~~through September 25, 2007, and can be accessed~~ by ~~dialing (800) 642-1687 or (706) 645-9291 and using~~ the ~~same~~undersigned ~~conference ID~~hereunto ~~number~~duly authorized.

~~-2-~~Leiner Health Products Inc.

~~Table~~By: of/s/ ~~Contents~~Heidi Crane Heidi Crane Chief Financial Officer

~~SIGNATURE~~Date March 10, 2008

~~Pursuant~~- to3 ~~the requirements of the Securities Exchange Act of 1934, the Registrant~~- ~~has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~

~~Date: September 17,~~EXHIBIT ~~2007~~INDEX

-3-


Exhibit
No.		Description

99.1		Press Release dated March 10, 2008.

- 4 -

Filing Compare · LEINER HEALTH PRODUCTS INC